(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 10.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 139.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.02%.
Veracyte's revenue in 2025 is $445,764,000.On average, 4 Wall Street analysts forecast VCYT's revenue for 2025 to be $38,093,402,806, with the lowest VCYT revenue forecast at $37,591,984,088, and the highest VCYT revenue forecast at $38,401,830,269. On average, 4 Wall Street analysts forecast VCYT's revenue for 2026 to be $41,975,598,065, with the lowest VCYT revenue forecast at $41,349,701,546, and the highest VCYT revenue forecast at $43,107,589,989.
In 2027, VCYT is forecast to generate $46,803,185,464 in revenue, with the lowest revenue forecast at $46,271,913,898 and the highest revenue forecast at $47,334,534,974.